Airflow limitation as a risk factor for vascular stiffness

S. S. Sheen; H. J. Kim; D. Singh; S. C. Hwang; K. J. Park; S. V. Ahn; E. Lee; B. Park; J. H. Jung; R. W. Park; J. H. Kim; H. S. Park; J. H. Park

doi:10.5588/ijtld.19.0457

Airflow limitation as a risk factor for vascular stiffness

S. S. Sheen, H. J. Kim, D. Singh, S. C. Hwang, K. J. Park, S. V. Ahn, E. Lee, B. Park, J. H. Jung, R. W. Park, J. H. Kim, H. S. Park, J. H. Park

Department of Health Convergence

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

BACKGROUND: Cardiovascular disease is one of the main causes of mortality in patients with chronic obstructive pulmonary disease (COPD), and atherosclerosis is a cause of cardiac comorbidities in COPD. However, it is not clear whether airflow limitation is associated with atherosclerosis irrespective of smoking. OBJECTIVE: To investigate whether airflow limitation is independently associated with vascular stiffness. METHODS: We enrolled 18 893 participants (male 70.5%; mean age 47.5 6 9.8 years; never smokers 44.2%) who underwent spirometry and brachial-ankle pulse wave velocity (baPWV) as part of a standard health examination at Ajou University Hospital, Suwon, South Korea, from January 2010 to December 2015. We defined vascular peripheral atherosclerosis as baPWV ≥ 1400 cm/s and airflow limitation as prebronchodilator ratio of forced expiratory volume in 1 sec (FEV₁) to forced vital capacity (FVC),70%. RESULTS: Mean baPWV was higher in subjects with airflow limitation (1477.6 6 331.7 cm/sec, n ¼ 638) than in those without airflow limitation (1344.1 6 231.8 cm/sec, n ¼ 18255, P, 0.001). In multivariate logistic regression analysis, the following were independent predictors associated with peripheral atherosclerosis (P, 0.05): age, male sex, fasting serum glucose, mean blood pressure, serum leukocyte count, serum low density lipoprotein level and FEV₁. CONCLUSION: Airflow limitation was an independent predictor of vascular stiffness irrespective of smoking history, which suggests that airflow limitation is linked with atherosclerosis.

Original language	English
Pages (from-to)	577-584
Number of pages	8
Journal	International Journal of Tuberculosis and Lung Disease
Volume	24
Issue number	6
DOIs	https://doi.org/10.5588/ijtld.19.0457
State	Published - 1 Jun 2020

Bibliographical note

Funding Information:
This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), Chungcheongbuk-do, South Korea, funded by the Ministry of Health & Welfare, Seoul, Republic of Korea (grant number : HI16C0992) Conflicts of interest: DS reports grants and personal fees from Apellis (Waltham, MA, USA), AstraZeneca (Cambridge, UK), Boehringer Ingleheim (Ingelheim am Rhein, Germany), Chiesi (Parma, Italy), Cipla (Mumbai, India), Glenmark (Mumbai, India), Merck (Kenilworth, NJ, USA), Mundipharma (Cambridge, UK), Novartis (Basel, Switzerland), Peptinnovate (Stevenage, UK), Pfizer (New York, NY, USA), Pulmatrix (Lexington, MA, USA), Teva (Petah Tikva, Israel), Therevance (South San Francisco, CA, USA) and Verona (London, UK), and personal fees from Genentech (South San Francisco, CA, USA) and Skyepharma (London, UK) outside the submitted work. Other authors have nothing to declare. Declaration: Data for this study will be provided on request.

Publisher Copyright:
© 2020 The Union.

Keywords

Airflow limitation
Atherosclerosis
Smoking

Access to Document

10.5588/ijtld.19.0457

Cite this

@article{2e9cb0a768524d45a800e361c8111c8f,

title = "Airflow limitation as a risk factor for vascular stiffness",

abstract = "BACKGROUND: Cardiovascular disease is one of the main causes of mortality in patients with chronic obstructive pulmonary disease (COPD), and atherosclerosis is a cause of cardiac comorbidities in COPD. However, it is not clear whether airflow limitation is associated with atherosclerosis irrespective of smoking. OBJECTIVE: To investigate whether airflow limitation is independently associated with vascular stiffness. METHODS: We enrolled 18 893 participants (male 70.5%; mean age 47.5 6 9.8 years; never smokers 44.2%) who underwent spirometry and brachial-ankle pulse wave velocity (baPWV) as part of a standard health examination at Ajou University Hospital, Suwon, South Korea, from January 2010 to December 2015. We defined vascular peripheral atherosclerosis as baPWV ≥ 1400 cm/s and airflow limitation as prebronchodilator ratio of forced expiratory volume in 1 sec (FEV1) to forced vital capacity (FVC),70%. RESULTS: Mean baPWV was higher in subjects with airflow limitation (1477.6 6 331.7 cm/sec, n ¼ 638) than in those without airflow limitation (1344.1 6 231.8 cm/sec, n ¼ 18255, P, 0.001). In multivariate logistic regression analysis, the following were independent predictors associated with peripheral atherosclerosis (P, 0.05): age, male sex, fasting serum glucose, mean blood pressure, serum leukocyte count, serum low density lipoprotein level and FEV1. CONCLUSION: Airflow limitation was an independent predictor of vascular stiffness irrespective of smoking history, which suggests that airflow limitation is linked with atherosclerosis.",

keywords = "Airflow limitation, Atherosclerosis, Smoking",

author = "Sheen, {S. S.} and Kim, {H. J.} and D. Singh and Hwang, {S. C.} and Park, {K. J.} and Ahn, {S. V.} and E. Lee and B. Park and Jung, {J. H.} and Park, {R. W.} and Kim, {J. H.} and Park, {H. S.} and Park, {J. H.}",

note = "Funding Information: This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), Chungcheongbuk-do, South Korea, funded by the Ministry of Health & Welfare, Seoul, Republic of Korea (grant number : HI16C0992) Conflicts of interest: DS reports grants and personal fees from Apellis (Waltham, MA, USA), AstraZeneca (Cambridge, UK), Boehringer Ingleheim (Ingelheim am Rhein, Germany), Chiesi (Parma, Italy), Cipla (Mumbai, India), Glenmark (Mumbai, India), Merck (Kenilworth, NJ, USA), Mundipharma (Cambridge, UK), Novartis (Basel, Switzerland), Peptinnovate (Stevenage, UK), Pfizer (New York, NY, USA), Pulmatrix (Lexington, MA, USA), Teva (Petah Tikva, Israel), Therevance (South San Francisco, CA, USA) and Verona (London, UK), and personal fees from Genentech (South San Francisco, CA, USA) and Skyepharma (London, UK) outside the submitted work. Other authors have nothing to declare. Declaration: Data for this study will be provided on request. Publisher Copyright: {\textcopyright} 2020 The Union.",

year = "2020",

month = jun,

day = "1",

doi = "10.5588/ijtld.19.0457",

language = "English",

volume = "24",

pages = "577--584",

journal = "International Journal of Tuberculosis and Lung Disease",

issn = "1027-3719",

publisher = "International Union Against Tuberculosis and Lung Disease (The Union)",

number = "6",

}

TY - JOUR

T1 - Airflow limitation as a risk factor for vascular stiffness

AU - Sheen, S. S.

AU - Kim, H. J.

AU - Singh, D.

AU - Hwang, S. C.

AU - Park, K. J.

AU - Ahn, S. V.

AU - Lee, E.

AU - Park, B.

AU - Jung, J. H.

AU - Park, R. W.

AU - Kim, J. H.

AU - Park, H. S.

AU - Park, J. H.

N1 - Funding Information: This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), Chungcheongbuk-do, South Korea, funded by the Ministry of Health & Welfare, Seoul, Republic of Korea (grant number : HI16C0992) Conflicts of interest: DS reports grants and personal fees from Apellis (Waltham, MA, USA), AstraZeneca (Cambridge, UK), Boehringer Ingleheim (Ingelheim am Rhein, Germany), Chiesi (Parma, Italy), Cipla (Mumbai, India), Glenmark (Mumbai, India), Merck (Kenilworth, NJ, USA), Mundipharma (Cambridge, UK), Novartis (Basel, Switzerland), Peptinnovate (Stevenage, UK), Pfizer (New York, NY, USA), Pulmatrix (Lexington, MA, USA), Teva (Petah Tikva, Israel), Therevance (South San Francisco, CA, USA) and Verona (London, UK), and personal fees from Genentech (South San Francisco, CA, USA) and Skyepharma (London, UK) outside the submitted work. Other authors have nothing to declare. Declaration: Data for this study will be provided on request. Publisher Copyright: © 2020 The Union.

PY - 2020/6/1

Y1 - 2020/6/1

N2 - BACKGROUND: Cardiovascular disease is one of the main causes of mortality in patients with chronic obstructive pulmonary disease (COPD), and atherosclerosis is a cause of cardiac comorbidities in COPD. However, it is not clear whether airflow limitation is associated with atherosclerosis irrespective of smoking. OBJECTIVE: To investigate whether airflow limitation is independently associated with vascular stiffness. METHODS: We enrolled 18 893 participants (male 70.5%; mean age 47.5 6 9.8 years; never smokers 44.2%) who underwent spirometry and brachial-ankle pulse wave velocity (baPWV) as part of a standard health examination at Ajou University Hospital, Suwon, South Korea, from January 2010 to December 2015. We defined vascular peripheral atherosclerosis as baPWV ≥ 1400 cm/s and airflow limitation as prebronchodilator ratio of forced expiratory volume in 1 sec (FEV1) to forced vital capacity (FVC),70%. RESULTS: Mean baPWV was higher in subjects with airflow limitation (1477.6 6 331.7 cm/sec, n ¼ 638) than in those without airflow limitation (1344.1 6 231.8 cm/sec, n ¼ 18255, P, 0.001). In multivariate logistic regression analysis, the following were independent predictors associated with peripheral atherosclerosis (P, 0.05): age, male sex, fasting serum glucose, mean blood pressure, serum leukocyte count, serum low density lipoprotein level and FEV1. CONCLUSION: Airflow limitation was an independent predictor of vascular stiffness irrespective of smoking history, which suggests that airflow limitation is linked with atherosclerosis.

AB - BACKGROUND: Cardiovascular disease is one of the main causes of mortality in patients with chronic obstructive pulmonary disease (COPD), and atherosclerosis is a cause of cardiac comorbidities in COPD. However, it is not clear whether airflow limitation is associated with atherosclerosis irrespective of smoking. OBJECTIVE: To investigate whether airflow limitation is independently associated with vascular stiffness. METHODS: We enrolled 18 893 participants (male 70.5%; mean age 47.5 6 9.8 years; never smokers 44.2%) who underwent spirometry and brachial-ankle pulse wave velocity (baPWV) as part of a standard health examination at Ajou University Hospital, Suwon, South Korea, from January 2010 to December 2015. We defined vascular peripheral atherosclerosis as baPWV ≥ 1400 cm/s and airflow limitation as prebronchodilator ratio of forced expiratory volume in 1 sec (FEV1) to forced vital capacity (FVC),70%. RESULTS: Mean baPWV was higher in subjects with airflow limitation (1477.6 6 331.7 cm/sec, n ¼ 638) than in those without airflow limitation (1344.1 6 231.8 cm/sec, n ¼ 18255, P, 0.001). In multivariate logistic regression analysis, the following were independent predictors associated with peripheral atherosclerosis (P, 0.05): age, male sex, fasting serum glucose, mean blood pressure, serum leukocyte count, serum low density lipoprotein level and FEV1. CONCLUSION: Airflow limitation was an independent predictor of vascular stiffness irrespective of smoking history, which suggests that airflow limitation is linked with atherosclerosis.

KW - Airflow limitation

KW - Atherosclerosis

KW - Smoking

UR - http://www.scopus.com/inward/record.url?scp=85086694780&partnerID=8YFLogxK

U2 - 10.5588/ijtld.19.0457

DO - 10.5588/ijtld.19.0457

M3 - Article

C2 - 32552994

AN - SCOPUS:85086694780

SN - 1027-3719

VL - 24

SP - 577

EP - 584

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

IS - 6

ER -

Airflow limitation as a risk factor for vascular stiffness

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this